null

Patritumab Biosimilar (Anti-HER3) Antibody (HDBS0056)

SKU:
HDBS0056
Product Type:
Biosimilar Antibody
Antibody Type:
Monoclonal Antibody
Protein:
HER-3
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
$479
Frequently bought together:

Description

system_update_altDatasheet

Patritumab (Anti-HER3) Biosimilar Antibody (HDBS0056)

The anti-HER3 (Patritumab Biosimilar) Antibody (HDBS0056) is a cutting-edge research tool designed for the detection and analysis of HER3, a cell surface receptor known for its role in cancer progression and resistance to multiple therapies. This antibody, developed using state-of-the-art technology, is highly specific and sensitive to HER3, making it an essential tool for studies in oncology and drug development.HER3, a member of the epidermal growth factor receptor (EGFR) family, plays a crucial role in promoting tumor growth and survival, making it a promising target for cancer therapy. The anti-HER3 antibody binds specifically to the HER3 protein, allowing researchers to investigate its expression levels and signaling pathways in cancer cells.

This knowledge is essential for developing targeted treatments and personalized therapies for patients with HER3-positive tumors.By using the anti-HER3 (Patritumab Biosimilar) Antibody (HDBS0056) in research, scientists can gain valuable insights into the mechanisms of HER3-mediated tumorigenesis and drug resistance. This antibody is validated for use in various experimental techniques, including immunohistochemistry, Western blot, and flow cytometry, enabling comprehensive analysis of HER3 expression and function in different cancer models. With its high quality and reliability, this antibody is a valuable asset for advancing our understanding of HER3 biology and developing novel therapeutic strategies for HER3-positive cancers.